Literature DB >> 17440955

Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy.

P Meijnen1, H S A Oldenburg, C E Loo, O E Nieweg, J L Peterse, E J T Rutgers.   

Abstract

BACKGROUND: The aim of the study was to assess the risk of invasion and axillary lymph node metastasis in patients with ductal carcinoma in situ (DCIS) diagnosed by preoperative core-needle biopsy. The data were used to select criteria for patients in whom sentinel node (SN) biopsy might be indicated.
METHODS: One hundred and seventy-one women with 172 DCIS lesions diagnosed by core-needle biopsy were analysed. Axillary staging was performed by SN biopsy, axillary node sampling, or level 1-2 axillary lymph node dissection.
RESULTS: Invasive breast cancer was found in the surgical specimens from 45 tumours (26.2 per cent). Risk factors for invasion were a palpable lesion (odds ratio (OR) 2.95 (95 per cent confidence interval 1.20 to 7.26); P = 0.019), presence of a mass on mammography (OR 3.06 (1.43 to 6.56); P = 0.004), and intermediate (OR 5.81 (1.18 to 28.57); P = 0.030) or poorly differentiated (OR 5.46 (1.17 to 25.64); P = 0.031) tumour grade. Lymph node metastases were found in ten women with DCIS and invasion on final pathology. Factors associated with metastases were age 55 years or less (P = 0.030), invasion of 1.0 cm or more (P < 0.001) and the presence of vascular invasion (P = 0.001).
CONCLUSION: SN biopsy should be considered in women with an initial diagnosis of DCIS on core-needle biopsy who are at risk for invasion; this includes women with a palpable lump, a mass on mammography, and intermediate or poor tumour grade. Copyright (c) 2007 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17440955     DOI: 10.1002/bjs.5735

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  14 in total

1.  MRI of the breast in patients with DCIS to exclude the presence of invasive disease.

Authors:  Eline E Deurloo; Jincey D Sriram; Hendrik J Teertstra; Claudette E Loo; Jelle Wesseling; Emiel J Th Rutgers; Kenneth G A Gilhuijs
Journal:  Eur Radiol       Date:  2012-02-26       Impact factor: 5.315

Review 2.  Is DCIS breast cancer, and how do I treat it?

Authors:  N Bijker; M Donker; J Wesseling; G J den Heeten; E J Th Rutgers
Journal:  Curr Treat Options Oncol       Date:  2013-03

3.  Sentinel lymph node biopsy in patients with breast ductal carcinoma in situ: Chinese experiences.

Authors:  Xiao Sun; Hao Li; Yan-Bing Liu; Zheng-Bo Zhou; Peng Chen; Tong Zhao; Chun-Jian Wang; Zhao-Peng Zhang; Peng-Fei Qiu; Yong-Sheng Wang
Journal:  Oncol Lett       Date:  2015-07-10       Impact factor: 2.967

Review 4.  The impact of sentinel lymph node biopsy and magnetic resonance imaging on important outcomes among patients with ductal carcinoma in situ.

Authors:  Todd M Tuttle; Tatyana Shamliyan; Beth A Virnig; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

5.  Sentinel Lymph Node Biopsy in Pure DCIS: Is It Necessary?

Authors:  D E Boler; N Cabioglu; U Ince; G Esen; C Uras
Journal:  ISRN Surg       Date:  2012-05-14

6.  A simple model to assess the probability of invasion in ductal carcinoma in situ of the breast diagnosed by needle biopsy.

Authors:  Oldřich Coufal; Iveta Selingerová; Pavlína Vrtělová; Petr Krsička; Lucie Gabrielová; Pavel Fabian; Kateřina Stískalová; Monika Schneiderová; Alexandr Poprach; Ivan Justan
Journal:  Biomed Res Int       Date:  2014-07-08       Impact factor: 3.411

7.  Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.

Authors:  L M van Roozendaal; B Goorts; M Klinkert; K B M I Keymeulen; B De Vries; L J A Strobbe; C A P Wauters; Y E van Riet; E Degreef; E J T Rutgers; J Wesseling; M L Smidt
Journal:  Breast Cancer Res Treat       Date:  2016-04-15       Impact factor: 4.872

8.  Development and evaluation of a prediction model for underestimated invasive breast cancer in women with ductal carcinoma in situ at stereotactic large core needle biopsy.

Authors:  Suzanne C E Diepstraten; Stephanie M W Y van de Ven; Ruud M Pijnappel; Petra H M Peeters; Maurice A A J van den Bosch; Helena M Verkooijen; Sjoerd G Elias
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

9.  Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ.

Authors:  Tomo Osako; Takuji Iwase; Masaru Ushijima; Rie Horii; Yasuyoshi Fukami; Kiyomi Kimura; Masaaki Matsuura; Futoshi Akiyama
Journal:  Cancer Sci       Date:  2014-03-26       Impact factor: 6.716

10.  Sentinel Lymph Node Biopsy Should Be Included with the Initial Surgery for High-Risk Ductal Carcinoma-In-Situ.

Authors:  Ern Yu Tan; Z W Joseph Lo; Chuan Han Ang; Christine Teo; Melanie D W Seah; Juliana J C Chen; Patrick M Y Chan
Journal:  Int Sch Res Notices       Date:  2014-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.